Three-dimensional quantitative structure-activity relationship studies on UGT1A9-mediated 3-O-glucuronidation of natural flavonols using a pharmacophore-based comparative molecular field analysis model

Journal of Pharmacology and Experimental Therapeutics

Volumn 336, Issue 2, 2011, Pages 403-413

  Wu, Baojian ^a   Morrow, John Kenneth ^b   Singh, Rashim ^a   Zhang, Shuxing ^b   Hu, Ming ^a  

^a UNIVERSITY OF HOUSTON   (United States)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 HYDROXY 2' METHOXYFLAVONE; 3 HYDROXY 2',3' DIMETHOXYFLAVONE; 3 HYDROXY 3' METHOXYFLAVONE; 3 HYDROXY 4' METHOXYFLAVONE; 3 HYDROXY 5 METHOXYFLAVONE; 3 HYDROXY 5,7 DIMETHOXYFLAVONE; 3 HYDROXY 6 METHOXYFLAVONE; 3 HYDROXY 6 METHYL 3',4' METHYLENEDIOXYFLAVONE; 3 HYDROXY 6 METHYLFLAVONE; 3 HYDROXY 6,4' METHOXYFLAVONE; 3 HYDROXY 7 METHOXYFLAVONE; 3 HYDROXYFLAVONE; 3,2' DIHYDROXYFLAVONE; 3,3' DIHYDROXYFLAVONE; 3,3',4' TRIHYDROXYFLAVONE; 3,4' DIHYDROXYFLAVONE; 3,5 DIHYDROXYFLAVONE; 3,6 DIHYDROXYFLAVONE; 3,6,4' TRIHYDROXYFLAVONE; 3,7 DIHYDROXYFLAVONE; FLAVONOL DERIVATIVE; GLUCURONOSYLTRANSFERASE 1A9; ISORHAMNETIN; KAEMPFEROL; MORIN; MYRICETIN; QUERCETIN; RESOKAEMPFEROL; RHAMNETIN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ARTICLE; COMPARATIVE MOLECULAR FIELD ANALYSIS; GLUCURONIDATION; PHARMACOPHORE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; STRUCTURE ACTIVITY RELATION;

FLAVONOLS; GLUCURONIDES; GLUCURONOSYLTRANSFERASE; HUMANS; MODELS, MOLECULAR; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 78751517809     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.110.175356     Document Type: Article

References (39)

1. Andersen OM and Markham KR (2006) Flavonoids - Chemistry, Biochemistry and Applications. CRC Taylor & Francis, Boca Raton, FL.
2. Barreca ML, Carotti A, Carrieri A, Chimirri A, Monforte AM, Calace MP, and Rao A (1999) Comparative molecular field analysis (CoMFA) and docking studies of non-nucleoside HIV-1 RT inhibitors (NNIs). Bioorg Med Chem 7:2283-2292. (Pubitemid 30122730)
3. Barve A, Chen C, Hebbar V, Desiderio J, Saw CL, and Kong AN (2009) Metabolism, oral bioavailability and pharmacokinetics of chemopreventive kaempferol in rats. Biopharm Drug Dispos 30:356-365.
4. Birt DF, Hendrich S, and Wang W (2001) Dietary agents in cancer prevention: flavonoids and isoflavonoids. Pharmacol Ther 90:157-177. (Pubitemid 32913477)
5. Chen Y, Xie S, Chen S, and Zeng S (2008) Glucuronidation of flavonoids by recombinant UGT1A3 and UGT1A9. Biochem Pharmacol 76:416-425.
6. Chen YK, Chen SQ, Li X, and Zeng S (2005) Quantitative regioselectivity of glucuronidation of quercetin by recombinant UDP-glucuronosyltransferases 1A9 and 1A3 using enzymatic kinetic parameters. Xenobiotica 35:943-954.
7. Chohan KK, Paine SW, and Waters NJ (2006) Quantitative structure activity relationships in drug metabolism. Curr Top Med Chem 6:1569-1578.
8. Christopoulos A and Lew MJ (2000) Beyond eyeballing: fitting models to experimental data. Crit Rev Biochem Mol Biol 35:359-391.
9. Cramer RD III, Patterson DE, and Bunce JD (1988) Comparative molecular field analysis (CoMFA). 1. Effect of shape on binding of steroids to carrier proteins. J Am Chem Soc 110:5959-5967.
10. D'Archivio M, Filesi C, Di Benedetto R, Gargiulo R, Giovannini C, and Masella R (2007) Polyphenols, dietary sources and bioavailability. Ann Ist Super Sanita 43:348-361.
11. Erlund I, Freese R, Marniemi J, Hakala P, and Alfthan G (2006) Bioavailability of quercetin from berries and the diet. Nutr Cancer 54:13-17.
12. Ethell BT, Ekins S, Wang J, and Burchell B (2002) Quantitative structure activity relationships for the glucuronidation of simple phenols by expressed human UGT1A6 and UGT1A9. Drug Metab Dispos 30:734-738. (Pubitemid 34579110)
13. Fisher MB, Paine MF, Strelevitz TJ, and Wrighton SA (2001) The role of hepatic and extrahepatic UDP-glucuronosyltransferases in human drug metabolism. Drug Metab Rev 33:273-297.
14. Fujiwara R, Nakajima M, Yamamoto T, Nagao H, and Yokoi T (2009) In silico and in vitro approaches to elucidate the thermal stability of human UDP-glucuronosyltransferase (UGT) 1A9. Drug Metab Pharmacokinet 24:235-244.
15. Haji-Momenian S, Rieger JM, Macdonald TL, and Brown ML (2003) Comparative molecular field analysis and QSAR on substrates binding to cytochrome p450 2D6. Bioorg Med Chem 11:5545-5554.
16. Holder S, Lilly M, and Brown ML (2007) Comparative molecular field analysis of flavonoid inhibitors of the PIM-1 kinase. Bioorg Med Chem 15:6463-6473.
17. Iyanagi T (2007) Molecular mechanism of phase I and phase II drug-metabolizing enzymes: implications for detoxification. Int Rev Cytol 260:35-112.
18. Jancova P, Anzenbacher P, and Anzenbacherova E (2010) Phase II drug metabolizing enzymes. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 154:103-116.
19. Joseph TB, Wang SW, Liu X, Kulkarni KH, Wang J, Xu H, and Hu M (2007) Disposition of flavonoids via enteric recycling: enzyme stability affects characterization of prunetin glucuronidation across species, organs, and UGT isoforms. Mol Pharm 4:883-894.
20. Laakkonen L and Finel M (2010) A molecular model of the human UDP-glucuronosyltransferase 1A1, its membrane orientation, and the interactions between different parts of the enzyme. Mol Pharmacol 77:931-939.
21. Luukkanen L, Taskinen J, Kurkela M, Kostiainen R, Hirvonen J, and Finel M (2005) Kinetic characterization of the 1A subfamily of recombinant human UDP-glucuronosyltransferases. Drug Metab Dispos 33:1017-1026.
22. Mackenzie PI, Bock KW, Burchell B, Guillemette C, Ikushiro S, Iyanagi T, Miners JO, Owens IS, and Nebert DW (2005) Nomenclature update for the mammalian UDP glycosyltransferase (UGT) gene superfamily. Pharmacogenet Genomics 15:677-685.
23. Miners JO, Smith PA, Sorich MJ, McKinnon RA, and Mackenzie PI (2004) Predicting human drug glucuronidation parameters: application of in vitro and in silico modeling approaches. Annu Rev Pharmacol Toxicol 44:1-25.
24. Ohno S and Nakajin S (2009) Determination of mRNA expression of human UDP-glucuronosyltransferases and application for localization in various human tissues by real-time reverse transcriptase-polymerase chain reaction. Drug Metab Dispos 37:32-40.
25. Osmani SA, Bak S, and Møller BL (2009) Substrate specificity of plant UDP-dependent glycosyltransferases predicted from crystal structures and homology modeling. Phytochemistry 70:325-347.
26. Otake Y, Hsieh F, and Walle T (2002) Glucuronidation versus oxidation of the flavonoid galangin by human liver microsomes and hepatocytes. Drug Metab Dispos 30:576-581. (Pubitemid 34456981)
27. Patana AS, Kurkela M, Finel M, and Goldman A (2008) Mutation analysis in UGT1A9 suggests a relationship between substrate and catalytic residues in UDP-glucuronosyltransferases. Protein Eng Des Sel 21:537-543.
28. Ross JA and Kasum CM (2002) Dietary flavonoids: bioavailability, metabolic effects, and safety. Annu Rev Nutr 22:19-34.
29. Rowland A, Elliot DJ, Williams JA, Mackenzie PI, Dickinson RG, and Miners JO (2006) In vitro characterization of lamotrigine N2-glucuronidation and the lamotrigine-valproic acid interaction.Drug Metab Dispos 34:1055-1062.
30. Said M, Ziegler JC, Magdalou J, Elass A, and Vergoten G (1996) Inhibition of bilirubin Udp-glucuronosyltransferase: a comparative molecular field analysis (COMFA). Quant Struct Act Relat 15:382-388.
31. max) generated from an online diode-arrayed detector. J Agric Food Chem 58:9384-9395.
32. Smith PA, Sorich MJ, Low LS, McKinnon RA, and Miners JO (2004) Towards integrated ADME prediction: past, present and future directions for modelling metabolism by UDP-glucuronosyltransferases. J Mol Graph Model 22:507-517.
33. Smith PA, Sorich MJ, McKinnon RA, and Miners JO (2003) In silico insights: chemical and structural characteristics associated with uridine diphosphate glucuronosyltransferase substrate selectivity. Clin Exp Pharmacol Physiol 30:836-840.
34. Sorich MJ, Smith PA, McKinnon RA, and Miners JO (2002) Pharmacophore and quantitative structure activity relationship modelling of UDP- glucuronosyltransferase 1A1 (UGT1A1) substrates. Pharmacogenetics 12:635-645.
35. Sorich MJ, Smith PA, Miners JO, Mackenzie PI, and McKinnon RA (2008) Recent advances in the in silico modelling of UDP glucuronosyltransferase substrates. Curr Drug Metab 9:60-69.
36. Tang L, Singh R, Liu Z, and Hu M (2009) Structure and concentration changes affect characterization of UGT isoform-specific metabolism of isoflavones. Mol Pharm 6:1466-1482.
37. Tang L, Ye L, Singh R, Wu B, Lv C, Zhao J, Liu Z, and Hu M (2010) Use of glucuronidation fingerprinting to describe and predict mono- and dihydroxyflavone metabolism by recombinant UGT isoforms and human intestinal and liver microsomes. Mol Pharm 7:664-679.
38. Wei DG, Yang GF, Wan J, and Zhan CG (2005) Binding model construction of antifungal 2-aryl-4-chromanones using CoMFA, CoMSIA, and QSAR analyses. J Agric Food Chem 53:1604-1611.
39. Wong YC, Zhang L, Lin G, and Zuo Z (2009) Structure-activity relationships of the glucuronidation of flavonoids by human glucuronosyltransferases. Expert Opin Drug Metab Toxicol 5:1399-1419.